Skip to content

U-100 unit conversion

Cortexin calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

10U-100 units · 0.1 mL

25 mcg per unit · 2500 mcg/mL

How the calculator works, sources and review dates

Cortexin math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 5 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-10. source-curated; clinician review pending.

Units chart for listed Cortexin sizes

U-100 math for listed Cortexin sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
5 mg502516.7
10 mg1005033.3

What is Cortexin?

Other names in the library: Cortexin 10mg — 10mg / Premium, Cortexin 10mg — 5mg (Out of stock) / Premium. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: 5 mg, 10 mg. A seller title is a listing. It does not prove the vial matches a paper.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Regulatory context

Regulatory context; not efficacy evidence

No matched controlled clinical study of this exact preparation was verified in this source audit.

Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.

Nonresponse. Nonresponse frequency not established in this excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.

Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human trial

Cortexin: multicenter placebo-controlled stroke study (2014)

272 patients in a multicenter double-blind placebo-controlled trial.

Reported findings. Authors reported functional improvement within complex stroke care.

Nonresponse. Nonresponse frequency not established in this excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Abstract lacks numeric effect estimates; clinical setting, background care and the exact preparation limit generalization. No healthy-person cognition benefit established.

Preparation: Source preparation; commercial equivalence unverified. Route: intramuscular

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Clinical observation

CORNELia: observational combination-treatment report (2023)

801 people aged 30–80 with chronic cerebral ischemia and cognitive impairment; 30-day observations.

Reported findings. Authors reported improved cognitive and depression scores with Cortexin plus Neuromexol.

Nonresponse. Nonresponse frequency not established in this excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Combination treatment and observational allocation prevent assigning change to Cortexin alone. Exact supplier identity remains unverified.

Preparation: Source preparation; commercial equivalence unverified. Route: intramuscular

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Human report

Public Cortexin focus and injection-site inflammation report

One anonymous public firsthand account; identity, preparation and clinical outcome are not independently verified.

Reported findings. Reporter perceived greater calm, focus, learning and sustained attention to tasks.

Nonresponse. Memory wording is ambiguous and is not encoded as definite improvement or deterioration.

Harms. Injection-site inflammation was reported; same-author preceding comment says it resolved within one or two days.

Limits. Preceding comment nmdqtpi and expanded comment nml4wra are one person’s report, not two independent reports. The reporter did not try Cerebrolysin; speculative comparison is not comparative efficacy evidence. Concurrent interventions and systematic clinical assessment unverified. Selection, reporting, placebo and preparation uncertainties remain. This account is not causal proof, a diagnosed outcome, a population response rate or established safety.

Preparation: Named Cortexin injection; mixture composition and supplier equivalence unverified. Route: Injection stated; intramuscular versus subcutaneous unspecified.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Human trial

[Cortexin in the comprehensive treatment of neurological complications of type 2 diabetes mellitus. (Results of the DIACORT multicenter randomized clinical trial)].

DIACORT:110 randomized at five Russian centers;109 completed, type2 diabetes with neurological complications.

Reported findings. Add-on group showed greater improvements in cognition, mood and neuropathy measures.

Nonresponse. Both groups improved on some outcomes; some deficits persisted.

Harms. Five adverse events: add-on urticaria, bacterial rhinitis and respiratory symptoms; control gastric pain and respiratory symptoms. Investigators judged them unrelated.

Limits. Open-label, envelope-randomized design limits attribution. Full methods clarify glycine was oral and B vitamins initially intramuscular then oral; compressed abstract wording must not be assigned to every background treatment. Proposed drug-delivery mechanism was not established by this trial.

Preparation: Trial medicinal Cortexin; commercial catalog mixture equivalence unverified. Route: Intramuscular add-on; background diabetes therapy, oral glycine and B vitamins were co-interventions.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Human trial

[Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes].

490 ischemic-stroke patients randomized:246 initialIV,244 initialIM.

Reported findings. Authors report IV noninferiority/equivalence to IM for functional recovery.

Nonresponse. MMSE changes4.11 versus3.88 did not differ significantly, p0.249.

Harms. 74 adverse events in60 initialIV participants versus51 events in41 initialIM participants; reported difference nonsignificant. Event types and relatedness unverified.

Limits. Both arms received active Cortexin; opposite-route placebo maintained blinding, not a no-Cortexin control. Route comparison does not establish absolute treatment benefit versus no Cortexin. Accessible abstract only; full methods and disclosures remain unverified.

Preparation: Active medicinal IV-versus-IM Cortexin preparations; manufacturing details and catalog mixture equivalence unverified. Route: Initial IV versus IM with opposite-route placebo; both groups subsequently received IM Cortexin.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

source limited. No matched controlled clinical study of this exact preparation was verified in this source audit.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

Risks and mix-ups already on the record

  • Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
  • No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
  • No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

  1. Regulatory context; not efficacy evidence · checked 2026-10-09
  2. Cortexin: multicenter placebo-controlled stroke study (2014) · checked 2026-10-09
  3. CORNELia: observational combination-treatment report (2023) · checked 2026-10-09

Questions people ask

Is Cortexin FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of Cortexin?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

How many units is a listed Cortexin vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.